Qvanteq AG develops novel bioactive stents to address and overcome the clinical adverse effects of today’s available coronary and endovascular stents. Qvanteq’s bioactive Qstent promises controlled in-growth therefore reducing the risk of restenosis and thrombosis.

Qvanteq AG was founded in early 2009 and is held by private investors. Qvanteq is
ISO 13485 certified. The company is based at the Technopark in Zurich, Switzerland.

Qvanteq is a spin-off company from the Swiss Federal Institute of Technology (ETH) Zurich. The company was awarded with the CTI start-up label in 2012.


Europe_Winners   cti_certified_label_color_small       Druck